42.20
+2.93%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Urteste
Its shares trade on GPW under the ticker URT.WA. It has been listed since 27 October 2021. In the fiscal year to 31 December 2024, it reported revenue of PLN 1.8m and a net loss of PLN 3.6m. At that date it held total assets of PLN 29.6m and shareholders' equity of PLN 24.1m.
Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Oct 2021
- Website
- urteste.eu ↗
Leadership
Pay as last reported
- Mr. Grzegorz StefanskiPresident of the Management Board
- Mr. Tomasz KostuchVice President of the Management Board
- Mr. Grzegorz BasakMember of the Supervisory Board
- Mr. Jaroslaw BilinskiMember of the Supervisory Board
- Mr. Maciej MatusiakMember of the Supervisory Board
- Ms. Magdalena WysockaMember of the Supervisory Board
- Kamil MajcherInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Urteste SA develops early cancer detection technology using urine enzyme activity for multiple cancer types.
- The company offers diagnostic tests for pancreatic, prostate, colorectal, and lung cancers in the Health Care sector.
- Urteste SA's IPO on 27 October 2021 established a strong market presence in Biotechnology.
Weaknesses
- Urteste SA operates from Gdansk, Woj. Pomorskie, which may limit its global reach in the Health Care industry.
- The company's focus on urine-based diagnostics could face competition from other medical device technologies.
- Urteste SA's business is limited to in vitro cancer diagnostics without broader medical applications.
Opportunities
- Urteste SA can expand its test offerings to include additional cancer types like ovarian and endometrial cancers.
- The growing demand for early cancer detection in the European market presents significant opportunities.
- Urteste SA may collaborate with healthcare providers in Poland and neighboring countries to increase adoption.
Threats
- Urteste SA faces potential regulatory challenges in the Health Care sector for new diagnostic technologies.
- The Biotechnology industry is highly competitive with established players in cancer diagnostics.
- Urteste SA's reliance on urine-based diagnostics could be disrupted by emerging alternative technologies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.